Catalyst Wire Dossier Catalyst Wire Dossier

Immune checkpoint inhibitor (unspecified)

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Immune checkpoint inhibitor (unspecified), covering 2024-08-13 to 2026-01-29. Get the full timeline:

Most recent: Clinical Trial Update: Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction [Phase 2]

See pricing